Thyroid Cancer Coverage from Every Angle
Advertisement
Advertisement

Giuseppe Curigliano, MD, PhD, on NSCLC and Thyroid Cancer: Treatment With a Selective RET Inhibitor

Posted: Thursday, March 12, 2020

Giuseppe Curigliano, MD, PhD, University of Milan, discusses treatment with BLU-667, a potent and selective RET inhibitor that provides rapid clearance of ctDNA in patients with RET-altered non–small cell lung cancer and thyroid cancer.

Advertisement
Advertisement


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.